Form 4: BioAffinity Technologies Director Peter Knight Reports Stock Grant

Director Peter Knight received a grant of restricted shares in BioAffinity Technologies, according to a recent SEC filing.

Summary

• Peter Knight, a director of bioAffinity Technologies, Inc., reported a transaction on July 1, 2024.
• Knight acquired 33,784 shares of common stock through a grant.
• The shares were granted at a price of $0.
• Following the transaction, Knight beneficially owns 117,455 shares of common stock.
• The grant consists of restricted shares that vest pro rata on a monthly basis over 12 months, starting August 1, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard stock grant to a director. It's neither overwhelmingly positive nor negative.

Positives

• The grant of shares to a director could align their interests with those of the shareholders.

Future Outlook

The restricted shares will vest over the next 12 months, starting August 1, 2024.

Industry Context

Stock grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with shareholders and incentivizing performance.

Stakeholder Impact

• The stock grant could potentially impact shareholders by aligning director incentives with company performance.

Key Dates

Keywords

Form 4, bioAffinity Technologies, BIAF, Peter Knight, stock grant, restricted shares, beneficial ownership, director